Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107
Przemyslaw Twardowski(Saint John's Health Center), Primo N. Lara(UC Davis Comprehensive Cancer Center), Catherine M. Tangen(American Urological Association), Elizabeth R. Plimack(Fox Chase Cancer Center), Melissa Plets(Cancer Research And Biostatistics), Xiwei Wu(City Of Hope National Medical Center), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Jinhui Wang(Wenzhou Medical University), Neeraj Agarwal(University of Utah), Shu Tao(City of Hope), Ian M. Thompson(The University of Texas at San Antonio Health Science Center)
Cited by 41
Related Papers
Frailty in Older Adults: Evidence for a Phenotype
|The Journals of Gerontology Series A|2001|24.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k